Eurofins Scientific ad hoc press release
Monday, June 3, 2019
Eurofins Scientific (EUFI.PA) today announced that during the weekend of 2nd June, its IT security monitoring teams detected a form of ransomware which caused disruption to some of its IT systems. Upon detection of the issue, according to our incident management procedures, many systems and servers were taken off line by the group’s IT teams to contain the activity of this new version of malware. Eurofins IT staff and their internal and external IT security teams and experts took immediate steps to mitigate the impact and are working hard to return the IT operations to normal in the companies of the group that have been affected. At this time there is no evidence of unauthorized transfer or misuse of data. The Eurofins companies affected are notifying the relevant authorities of this IT incident and will cooperate in any investigation.
Eurofins IT teams are working hard to quickly resolve the situation and to resume the high level of service expected from all Eurofins companies. This includes installing additional protections against this new variant of malware which were received over the weekend and restoring affected systems from backups after appropriate security verifications. As this may be taking some time, Eurofins apologizes to the customers of those of its laboratories and sites that may be impacted for the potential temporary disruption or delays to some of its services. Each group company concerned will be contacting affected customers with further information as needed.
For more information, please visit www.eurofins.com or contact:
Phone: +32 2 766 1620
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is a scientific leader in food, environment, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the leading global emerging players in specialty clinical diagnostic testing. With about 45,000 staff in more than 800 laboratories across 47 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.